Skip to main content

Small Molecule Deal Benchmarks in Immunology & Autoimmune

Median Upfront
$466M
Range: $247M - $675M
Total Deal Value
$2.4B
Range: $1.5B - $3.4B
Royalty Rate
13.1% - 21.9%
Tiered up to 25.9%
Dev Milestones
$393M
Range: $252M - $536M
Model Your Deal

Market Analysis

Small Molecule therapies in immunology & autoimmune have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 small molecule asset in immunology & autoimmune is $466M, with total deal values reaching $2.4B. Development milestones average $393M, while regulatory milestones contribute $688M.

The immunology & autoimmune small molecule landscape is characterized by high competitive intensity, particularly in inflammatory bowel disease and autoimmune conditions. CAR-T for autoimmune diseases, TL1A inhibitors, and next-generation targeted therapies are reshaping the licensing landscape. The recommended deal structure allocates approximately 19% to upfront payments and 81% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for small molecule immunology & autoimmune deals range from 13.1% to 21.9% at the base tier, with tiered escalation reaching 17.1%-25.9% on blockbuster sales. Commercial milestones averaging $884M further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a small molecule immunology & autoimmune licensing deal?
Based on our analysis, Phase 2 small molecule licensing deals in immunology & autoimmune average $466M in upfront payments, with a range of $247M to $675M depending on data quality, competitive positioning, and territorial scope.
What is the total deal value for small molecule immunology & autoimmune transactions?
The median total deal value for Phase 2 small molecule assets in immunology & autoimmune is $2.4B, ranging from $1.5B to $3.4B. This includes development milestones ($393M), regulatory milestones ($688M), and commercial milestones ($884M).
What royalty rates are standard for small molecule deals in immunology & autoimmune?
Base royalty rates for small molecule immunology & autoimmune transactions range from 13.1% to 21.9%, with tiered escalations reaching 17.1%-25.9% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.
How are milestones structured in small molecule immunology & autoimmune deals?
Small Molecule immunology & autoimmune deals allocate approximately 81% of total deal value to milestones. Development milestones ($393M) make up the largest share, followed by commercial milestones ($884M) and regulatory milestones ($688M).
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Monoclonal Antibody in Immunology & Autoimmune

View

Bispecific Antibody in Immunology & Autoimmune

View

Small Molecule in Oncology

View

Small Molecule in Neurology

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included